Table 2.
Ovarian function after ovarian tissue cryopreservation and treatment
| Ovarian function | All patients (n = 51a) n – (%) | Breast cancer (n = 21) n – (%) | Osteosarcoma (n = 6) n – (%) |
|---|---|---|---|
| Premature ovarian insufficiency | 20 – (39.2%)b | 9 – (42.6%)c | 0 (0%) |
| >12 mo amenorrhea and/or FSH > 40 IU/L | 15 | 5 | 0 |
| BSO/additional oophorectomy | 4 | 3 | 0 |
| Additional oophorectomy + hysterectomy | 1 | 1 | 0 |
| Normal ovarian function | 23 – (45.1%) | 11 – (52.4%) | 5 – (83.3%) |
| Pregnant without transplantation | 14 – (27.4%) | 9 – (42.9%) | 2 – (33%) |
| Unknown | 8 – (11.8%) | 1 – (4.8%) | 1 – (16.7%) |
| Contraception (hormonal) | 6 | — | 1 |
| <1 y treatment | 1 | 1 | |
| Premenarchal | 1 | — | |
| Total | 51 – (100%) | 21 – (100%) | 6 – (100%) |
One patient who is not included in the table, delivered a healthy baby and died afterward due to disease recurrence.
Abbreviations: BSO, bilateral salpingo‐oophorectomy; FSH, follicle‐stimulating hormone.
a
Excludes 12 diseased, 6 lost to follow up.
b
Corrected for BSO and oophorectomy of the remaining ovary = 15 (29.4%).
c
Corrected for oophorectomy of the remaining ovary = 4 (23.8%).